Benitec Biopharma Inc.
Benitec Biopharma Inc. is listed today as Benitec Biopharma Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2024 | $40 M | Private placement after listing | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Benitec Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).
SEC Form D · Apr 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2024
That is all the official record says: Benitec Biopharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Benitec Biopharma Inc. are on record.
Investors#
No investor of Benitec Biopharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Benitec Biopharma Inc. shares, as of Sep 30, 2026.
- Montanova Capital, LLC$115 M33.11%
- Franklin Templeton Inc$24 M6.92%
- Janus Henderson Group Ltd.$23 M6.73%
- Adage Capital Partners GP, L.L.C.$21 M6.08%
- Ra Capital Management, L.P.$19 M5.30%
- Nantahala Capital Management, LLC$17 M4.81%
- BlackRock, Inc.$14 M4.09%
- Infinitum Asset Management, LLC$13 M3.61%
- Vanguard Capital Management LLC$10 M2.97%
- Simplify Asset Management Inc.$10 M2.87%
- Millennium Management LLC$8 M2.18%
- Alyeska Investment Group, L.P.$8 M2.15%
- Geode Capital Management, LLC$7 M1.91%
- Balyasny Asset Management L.P.$6 M1.86%
- Silverarc Capital Management, LLC$4 M1.27%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jerel Banks | Executive officer | Apr 2024 |
| Megan Boston | Executive officer | Apr 2024 |
| Edward Kevin Smith | Director | Apr 2024 |
| J. Kevin Buchi | Director | Apr 2024 |
| Jerel Banks | Director | Apr 2024 |
| Megan Boston | Director | Apr 2024 |
| Peter Kevin Francis | Director | Apr 2024 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.